Ambugreen is a ground-breaking gel barrier that features unique patented technology.
Momentum Bioscience, a biotech company pioneering rapid sepsis diagnostics, has relocated to Oxfordshire’s Milton Park, the UK’s largest single-ownership innovation community.
Qureight will integrate its deep-learning technology into the study, providing imaging core lab services.
Robotic harvesting specialist appoints Blue River Technology co-founder as new chairman of the board.
Sphere Fluidics today announced its rebranding to Sphere Bio. The name change marks a significant milestone in the company’s development, reflecting its transition from a leading droplet-based microfluidics innovator to an established commercial provider of integrated life sciences tools and solutions.
Neuroscience startup Monument Therapeutics has developed MT1988, a novel fixed-dose combination drug for the cognitive impairment associated with schizophrenia.
Nearly 20 subjects in the US are being enrolled for the trial.
Oxford Drug Design has been awarded £1 ($1.2) million in funding to progress its uUTI (uncomplicated urinary tract infection) antibacterial programme from PACE (Pathways to Antimicrobial Clinical Efficacy).
Cambridge-based FLIT, an engineering company that builds folding electric bikes for urban commuters, has raised £1.2 million in new funding. The cash injection will be used to scale up production of its latest model, the FLIT M2 at the company’s Cambridge facility.
The Newcastle University spinout will use the funds to develop the company’s sales and drive widespread adoption of its biological transport technology.
Anglo / German partnership harnesses AI to redefine market intelligence for total innovation
Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat life-threatening pulmonary diseases, have announced the initiation of a strategic partnership in progressive pulmonary fibrosis.